MacroGenics reports Phase I data of flotetuzumab for AML

MacroGenics Inc. (NASDAQ:MGNX) reported preliminary data from 8 evaluable patients with acute myelogenous leukemia (AML) in a dose-expansion cohort of a Phase

Read the full 226 word article

User Sign In